BCRX
BioCryst Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26
Figures on this page computed 2026-11-08 12:48 UTC
Last close
7.63USD
Market data, 2026-11-05
Except where said otherwise: 10-K for 2025, filed 2026-02-26
6.1xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
30.2%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
39.4%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Safety is the furthest below its sector's middle: 0.49 against 0.53 on the market's range.
- Growth117.9%97 of 100, above its sector
- Returns on capital51.3%100 of 100, above its sector
- Margins97.8%96 of 100, above its sector
- Price6.1x71 of 100, above its sector
- Safety2.0649 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 2 of 4- Profit on each unit of sales30.2%39.2%Behind
Higher is better here.
- Return on the capital it usesn/an/an/a
Higher is better here.
- Sales growth over five years118%18.8%Ahead
Higher is better here.
- Debt against equityn/an/an/a
Lower is better here.
- Gross margin97.8%93.5%Ahead
Higher is better here.
- Price against earnings6.1x4.0xBehind
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Novavax, Inc., BCRX is behind on 2 of 4 measures.
Against Novavax, Inc., BCRX is behind on 2 of 4 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-26
Profit on each unit of sales30.2%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
Return on the capital it usesn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
Sales growth over five years117.9%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
Debt against equityn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
Gross margin97.8%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
Price against earnings6.1x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD